中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

50 records (took 0.019 seconds)

    METHOD OF ISOLATING ANALYTES FROM A SAMPLE
    4.
    发明申请
    METHOD OF ISOLATING ANALYTES FROM A SAMPLE 审中-公开
    从样本中分离分析物的方法

    公开(公告)号：WO2007038523A2

    公开(公告)日：2007-04-05

    申请号：PCT/US2006/037508

    申请日：2006-09-27

    Applicant: CENTER FOR APPLIED PROTEOMICS AND MOLECULAR MEDICINE ,  LIOTTA, Lance ,  PETRICOIN, Emanuel ,  GEHO, David

    Inventor： LIOTTA, Lance ,  PETRICOIN, Emanuel ,  GEHO, David

    IPC: G01N33/543

    CPC classification number: G01N33/54346 ,  Y10T428/2982 ,  Y10T428/2991 ,  Y10T428/2998

    Abstract: The current invention is a capture-particle comprising: a) a molecular sieve portion; and b) an analyte binding portion; wherein the molecular sieve portion, analyte binding portion or both further comprise a cross-linked region having modified porosity. Capture particles wherein the molecular sieve portion, analyte binding portion or both comprise pore dimensions sufficient to exclude molecules larger than about 60 kDa. These particles are useful in purification and diagnostic methods. Kits comprising the capture particles are also described.

    Abstract translation: 本发明是一种捕获颗粒，其包含：a）分子筛部分; 和b）分析物结合部分; 其中分子筛部分，分析物结合部分或两者还包含具有改变的孔隙度的交联区域。 俘获粒子，其中分子筛部分，分析物结合部分或两者包含足以排除大于约60kDa的分子的孔尺寸。 这些颗粒可用于纯化和诊断方法。 还描述了包含捕获颗粒的试剂盒。

    SERUM BIOMARKER FOR DISEASE AND METHODS OF USING SAME
    5.
    发明申请
    SERUM BIOMARKER FOR DISEASE AND METHODS OF USING SAME 审中-公开
    用于疾病的血清生物标志物及其使用方法

    公开(公告)号：WO2006108095A9

    公开(公告)日：2006-11-23

    申请号：PCT/US2006012803

    申请日：2006-04-06

    Applicant: UNIV MARYLAND ,  US GOV HEALTH & HUMAN SERV ,  MELTZER STEPHEN ,  KAN TAKATSUGU ,  PETRICOIN EMANUEL

    Inventor： MELTZER STEPHEN ,  KAN TAKATSUGU ,  PETRICOIN EMANUEL

    IPC: G01N33/574

    CPC classification number: G01N33/57446 ,  C07K16/3046

    Abstract: The present invention relates to methods of diagnosing abnormal conditions subjects, with the methods comprising determining the levels of a biomarker in a sample the subject, where the biomarker is selected from the group consisting of a peptide comprising an amino acid sequence at least 80% identical to the amino acid sequence of SEQ ID NO:1 and a peptide having a mass:charge ratio of about 771.88 daltons. The levels of biomarker in the test subject are then compared to normal levels of the biomarker. Any differences between the levels of the biomarker in the test subject and normal levels are indicative of the presence of an abnormal condition in said subject.

    Abstract translation: 本发明涉及诊断异常病症受试者的方法，其方法包括确定受试者样品中生物标志物的水平，其中生物标志物选自包含至少80％相同的氨基酸序列的肽 与SEQ ID NO：1的氨基酸序列和质量：充电比为约771.88道尔顿的肽。 然后将测试受试者中的生物标记物的水平与生物标志物的正常水平进行比较。 测试对象中生物标志物水平和正常水平之间的任何差异都表明所述受试者存在异常状况。

    MULTIPLE HIGH-RESOLUTION SERUM PROTEOMIC FEATURES FOR OVARIAN CANCER DETECTION
    6.
    发明申请
    MULTIPLE HIGH-RESOLUTION SERUM PROTEOMIC FEATURES FOR OVARIAN CANCER DETECTION 审中-公开
    用于卵巢癌检测的多种高分辨率血清胰岛素特征

    公开(公告)号：WO2005011474A2

    公开(公告)日：2005-02-10

    申请号：PCT/US2004/024413

    申请日：2004-07-30

    Applicant: CORRELOGIC SYSTEMS, INC. ,  THE UNITED STATES OF AMERICA as represented by the secretary of THE DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  HITT, Ben, A. ,  LEVINE, Peter, A. ,  LIOTTA, Lance, A. ,  PETRICOIN, Emanuel, F.

    Inventor： HITT, Ben, A. ,  LEVINE, Peter, A. ,  LIOTTA, Lance, A. ,  PETRICOIN, Emanuel, F.

    IPC: A61B

    CPC classification number: G06F19/18 ,  G06F19/24

    Abstract: A well-controlled serum study set ( n = 248) from women being followed and evaluated for the presence of ovarian cancer was used to extend serum proteomic pattern analysis to a higher resolution mass spectrometer instrument platform to explore the existence of multiple distinct highly accurate diagnostic sets of features present in the same mass spectrum. Multiple highly accurate diagnostic proteomic feature sets exist within human sera mass spectra. Using high-resolution mass spectral data, at least 56 different patterns were discovered that achieve greater than 85 % sensitivity and specificity in testing and validation. Four of those feature sets exhibited 100 % sensitivity and specificity in blinded validation. The sensitivity and specificity of diagnostic models generated from high-resolution mass spectral data were superior ( P

    Abstract translation: 使用来自妇女的良好控制的血清研究组（n = 248）并评估卵巢癌的存在，将血清蛋白质组学模式分析扩展到更高分辨率的质谱仪仪器平台，以探索存在多种不同的高精度诊断 在同一质谱中存在的特征集合。 人血清质谱中存在多个高度准确的诊断蛋白质组特征集。 使用高分辨率质谱数据，发现了至少56种不同的模式，其在测试和验证中实现了大于85％的灵敏度和特异性。 其中四个特征集在盲法验证中表现出100％的灵敏度和特异性。 从高分辨率质谱数据生成的诊断模型的灵敏度和特异性优于使用相同输入样本的低分辨率质谱数据产生的诊断模型的灵敏度和特异性（P <0.00001）。

    EX VIVO THERAPEUTIC SCREENING OF LIVING BONE MARROW CELLS FOR MULTIPLE MYELOMA
    7.
    发明申请
    EX VIVO THERAPEUTIC SCREENING OF LIVING BONE MARROW CELLS FOR MULTIPLE MYELOMA 审中-公开
    用于多发性骨髓瘤的生物骨髓细胞的VIVO治疗筛选

    公开(公告)号：WO2010019227A1

    公开(公告)日：2010-02-18

    申请号：PCT/US2009/004608

    申请日：2009-08-12

    Applicant: GEORGE MASON INTELLECTUAL PROPERTIES, INC. ,  ESPINA, Virginia ,  LIOTTA, Lance ,  PETRICOIN, Emanuel, F.

    Inventor： ESPINA, Virginia ,  LIOTTA, Lance ,  PETRICOIN, Emanuel, F.

    IPC: G01N33/48

    CPC classification number: G01N33/56972 ,  G01N33/5011 ,  G01N2333/70596 ,  G01N2510/00 ,  G01N2800/52

    Abstract: Methods of selecting a treatment for a patient with multiple myeloma are provided. Prior to commencing a treatment regime, bone marrow aspirates are isolated from a patient and incubated with one or more candidate therapeutics. The methods identify the therapy or combination of therapies most likely to yield the best results for a particular individual. In addition to improving clinical outcome, such theranostic evaluations dramatically reduce health care costs, by avoiding ineffective therapies. Screening assays for identifying treatments for multiple myeloma also are provided.

    Abstract translation: 提供了选择多发性骨髓瘤患者的治疗方法。 在开始治疗方案之前，从患者中分离骨髓抽吸物并与一种或多种候选治疗剂一起温育。 该方法确定最有可能为特定个体产生最佳结果的治疗或疗法组合。 除了改善临床结果之外，这种诊断性评估通过避免无效疗法，大大降低了医疗保健成本。 还提供了用于鉴定多发性骨髓瘤治疗的筛选试验。

    TISSUE PRESERVATION AND FIXATION METHOD
    8.
    发明申请
    TISSUE PRESERVATION AND FIXATION METHOD 审中-公开
    组织保存和固定方法

    公开(公告)号：WO2008073187A3

    公开(公告)日：2009-12-23

    申请号：PCT/US2007022744

    申请日：2007-10-26

    Applicant: GEORGE MASON INTELLECTUAL PROP ,  LIOTTA LANCE A ,  PETRICOIN EMANUEL F ,  GEHO DAVID ,  ESPINA VIRGINIA A

    Inventor： LIOTTA LANCE A ,  PETRICOIN EMANUEL F ,  GEHO DAVID ,  ESPINA VIRGINIA A

    IPC: A01N1/00 ,  G01N1/30

    CPC classification number: G01N1/30 ,  A01N1/00

    Abstract: This invention relates, e.g., to a composition that, at room temperature, when contacted with a sample comprising phosphoproteins, can fix and stabilize cellular phosphoproteins, preserve cellular morphology, and allow the sample to be frozen to generate a cryostat frozen section suitable for molecular analysis. The composition comprises ( 1 ) a fixative that is effective to fix the phosphoproteins, and that has a sufficient water content to be soluble for a stabilizer and/or a permeability enhancing agent); (2) a stabilizer, comprising (a) a kinase inhibitor and (b) a phosphatase inhibitor and, optionally, (c) a protease (e.g., proteinase) inhibitor; and (3) a permeability enhancing agent (e.g. PEG). Methods are described for preserving phosphoproteins, using such a composition. Also described are endogenous surrogate markers for monitoring protein degradation, including the loss of posttranslational modifications (such as phosphorylation), e.g. the following removal of a cell or tissue from a subject; and exogenous molecular sentinels (e.g. phosphoproteins attached to magnetic nanoparticles) that allow one to evaluate the processing history of a cellular or tissue population sample.

    Abstract translation: 本发明涉及例如在室温下与包含磷蛋白的样品接触时可以固定和稳定细胞磷酸蛋白的组合物，保留细胞形态，并允许样品冷冻以产生适于分子的低温恒温器冷冻部分 分析。 组合物包含（1）固定磷酸蛋白有效的固定剂，并且其具有足够的水含量可溶于稳定剂和/或渗透性增强剂）; （2）稳定剂，其包含（a）激酶抑制剂和（b）磷酸酶抑制剂和任选的（c）蛋白酶（例如蛋白酶）抑制剂; 和（3）渗透性增强剂（例如PEG）。 描述了使用这种组合物来保存磷蛋白的方法。 还描述了用于监测蛋白质降解的内源替代标记，包括翻译后修饰（例如磷酸化）的丧失，例如， 以下从受试者中除去细胞或组织; 和外源性分子前哨蛋白（例如连接到磁性纳米颗粒的磷酸蛋白），其允许评价细胞或组织群体样品的加工历史。

    METHOD FOR PREDICTING RESPONSE TO TAMOXIFEN
    9.
    发明申请
    METHOD FOR PREDICTING RESPONSE TO TAMOXIFEN 审中-公开
    预测对TAMOXIFEN反应的方法

    公开(公告)号：WO2009014761A3

    公开(公告)日：2009-05-14

    申请号：PCT/US2008009105

    申请日：2008-07-28

    Applicant: GEORGE MASON INTELLECTUAL PROP ,  PETRICOIN EMANUEL F III ,  LIOTTA LANCE A ,  WULFKUHLE JULIA D

    Inventor： PETRICOIN EMANUEL F III ,  LIOTTA LANCE A ,  WULFKUHLE JULIA D

    IPC: G01N33/50

    CPC classification number: G01N33/57415 ,  G01N2800/52

    Abstract: This invention relates, e.g., to a method for predicting the response of a subject having, or at risk of developing, breast cancer to Tamoxifen therapy. The method comprises measuring the amount of phosphorylation at residues S70 of Bcl-2, Y992 of EGFR, and/or Y527 of Src in a suitable sample from the subject, wherein a statistically significantly elevated level of phosphorylation at one or more of the three residues compared to a baseline value indicates that the subject is likely to be responsive to Tamoxifen therapy.

    Abstract translation: 本发明涉及例如用于预测患有乳腺癌或有患乳腺癌风险的受试者对他莫昔芬疗法的反应的方法。 该方法包括测量来自受试者的合适样品中Bcl-2的残基S70，EGFR的残基S90，和/或Src的Y527的磷酸化的量，其中三个残基中的一个或多个的统计学显着升高的磷酸化水平 与基线值相比表明受试者可能对他莫昔芬治疗有反应。

    POST-EXPOSURE PROPHYLAXIS AND TREATMENT OF INFECTIONS CAUSED BY ANTHRAX
    10.
    发明申请
    POST-EXPOSURE PROPHYLAXIS AND TREATMENT OF INFECTIONS CAUSED BY ANTHRAX 审中-公开
    暴露后预防和治疗由ANTHRAX引起的感染

    公开(公告)号：WO2008115707A3

    公开(公告)日：2009-04-16

    申请号：PCT/US2008056038

    申请日：2008-03-06

    Applicant: GEORGE MASON INTELLECTUAL PROP ,  POPOV SERGUEI G ,  POPOVA TAISSIA ,  ESPINA VIRGINIA ,  BAILEY CHARLES ,  LIOTTA LANCE A ,  PETRICOIN EMANUEL

    Inventor： POPOV SERGUEI G ,  POPOVA TAISSIA ,  ESPINA VIRGINIA ,  BAILEY CHARLES ,  LIOTTA LANCE A ,  PETRICOIN EMANUEL

    IPC: A61K31/496 ,  A61K45/06 ,  A61P31/04

    CPC classification number: A61K45/06 ,  A61K31/496 ,  A61K2300/00

    Abstract: The invention provides methods and materials for identifying agents for preventing and/or treating anthrax and similar diseases. Embodiments provide strains and model systems for studying non-lethal and lethal exposure to anthrax and similar disease vectors. Embodiments provide materials and methods for using the strains and model systems for differential profiling, such as proteomic profiling, such as differentiation phosphorylation profiling, to target identification and therapeutics discovery and development. Embodiments provide pharmaceutically acceptable compositions, and methods for using them to prevent and/or treat anthrax and similar diseases comprising an agent that decreases the activity of caspase 1/4, such as YVAD, and/or an agent that increases the phosphorylation of AKT, such as IB-MECA or Cl-IB-MECA, together with, in particular embodiments, an antibiotic, such as ciprofloxacin. Kits comprising the same are provided as well, among other things.

    Abstract translation: 本发明提供用于鉴定用于预防和/或治疗炭疽和类似疾病的药剂的方法和材料。 实施例提供用于研究非致死和致死性暴露于炭疽和类似疾病载体的菌株和模型系统。 实施例提供了使用菌株和模型系统进行差异谱分析的材料和方法，例如蛋白质组学分析，例如分化磷酸化分析，靶向鉴定和治疗发现和发展。 实施方案提供了药学上可接受的组合物，以及使用它们来预防和/或治疗炭疽和类似疾病的方法，所述疾病包括降低半胱天冬酶1/4的活性的试剂，例如YVAD，和/或增加AKT磷酸化的试剂， 例如IB-MECA或Cl-IB-MECA，以及在具体实施方案中，抗生素，如环丙沙星。 还提供了包括其的套件，以及其他。

Patent Agency Ranking